The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
CONCLUSION: The primary patency rates in the analysis of the TASC C/D de novo lesion subgroup of the Zilver PTX Single Arm Study indicate that endovascular therapy outcomes with a paclitaxel eluting stent may equal those of bypass surgery. Endovascular treatment with DES may play an important role for treatment of patients who present with TASC C or D femoropopliteal lesions.
PMID: 23296421 [PubMed - in process]
Source: The Journal of Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S Tags: J Cardiovasc Surg (Torino) Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Heart | Orthopaedics | Study